Leerink Partnrs Comments on Repligen FY2024 Earnings

Repligen Co. (NASDAQ:RGEN) – Stock analysts at Leerink Partnrs issued their FY2024 EPS estimates for Repligen in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst P. Souda forecasts that the biotechnology company will earn $1.55 per share for the year. The consensus estimate for Repligen’s current full-year earnings is $1.44 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2024 earnings at $0.39 EPS, Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.80 EPS and FY2026 earnings at $2.47 EPS.

Several other brokerages have also weighed in on RGEN. Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday. They issued a “peer perform” rating on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Finally, UBS Group decreased their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Down 5.3 %

Shares of Repligen stock opened at $142.43 on Friday. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The business’s 50 day simple moving average is $141.59 and its 200-day simple moving average is $144.78.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.23 EPS.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently added to or reduced their stakes in RGEN. Andra AP fonden bought a new stake in shares of Repligen during the second quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new stake in shares of Repligen in the 2nd quarter worth about $33,000. UMB Bank n.a. boosted its position in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares in the last quarter. Lazard Asset Management LLC grew its stake in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.